Abstracts Archive - Page 2128 of 2607 - ACR Meeting Abstracts

Abstract Number: 1583 • 2014 ACR/ARHP Annual Meeting
Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp
M.C. Karreman¹, A.E.a.M. Weel^1,2, M. van der Ven¹, M. Vis³, I. Tchetverikov⁴, M. Wakkee⁵, T.E.C. Nijsten⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose Psoriatic Arthritis (PsA) is a progressive inflammatory joint disease that can lead to severe joint damage. New treatment strategies can be very effective in…
Abstract Number: 1602 • 2014 ACR/ARHP Annual Meeting
Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis
Siba Raychaudhuri¹, Anupam Mitra², Ananya Datta Mitra³, Christine Abria⁴ and Smriti K. Raychaudhuri³, ¹Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, ²Dermatology, VA Sacramento Medical Center, Mather, CA, ³Rheumatology, VA Sacramento Medical Center, Mather, CA, ⁴Research, VA Sacramento Medical Center, Mather, CA
Background/Purpose: Interleukin (IL)-9, a member of IL-2 cytokine family was recently attributed to a novel CD4 T cell subset termed Th9 cells in the murine…
Abstract Number: 1601 • 2014 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?
John Kelsall¹, William Bensen², Wojciech Olszynski³, Niall Jones⁴, Isabelle Fortin⁵, Andrew Chow⁶, Milton Baker⁷, Saeed Shaikh⁸, Denis Choquette⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, May Shawi¹¹, Francois Nantel¹¹, Susan Otawa¹² and Allen J Lehman¹², ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁵Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁶McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ⁷University of Victoria, Victoria, BC, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women whereas psoriatic arthritis (PsA) is generally considered a disease…
Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting
Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?
Rodolfo Perez Alamino¹, Raquel Cuchacovich², Arnold Zea³ and Luis R. Espinoza⁴, ¹internal Medicine, LSUHSC, New Orleans, LA, ²Rheumatology, LSU Medical Center, New Orleans, LA, ³Stanley Scott Cancer Center, New Orleans, LA, ⁴Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA
Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting
Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study
Agnes Szentpetery¹, Eric J. Heffernan², Muhammad Haroon³, Phil Gallagher¹, Anne-Marie Baker¹, Martina Cooney¹ and Oliver FitzGerald¹, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Radiology, St. Vincent's University Hospital, Dublin, Ireland, ³Newmarket On Fergus, Cork University Hospital, Cork, Ireland
Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
Abstract Number: 1577 • 2014 ACR/ARHP Annual Meeting
Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Philip J. Mease², Laura C. Coates³, Iain B. McInnes⁴, Maja Hojnik⁵, Alex Dorr⁶, Ying Zhang⁶, Benoit Guerette⁶, Alan Friedman⁶ and Dafna D. Gladman⁷, ¹University of California San Diego, La Jolla, CA, ²Swedish Medical Center and University of Washington, Seattle, WA, ³NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵AbbVie, Ljubljana, Slovenia, ⁶AbbVie, Inc., North Chicago, IL, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose The prediction of treatment outcomes based on early response could be useful in guiding decisions to adjust therapy. The objective was to determine if…
Abstract Number: 1576 • 2014 ACR/ARHP Annual Meeting
Reversal of Damage in Psoriatic Arthritis
Amir Haddad¹, Ker-Ai Lee², Arane Thavaneswaran¹, Vinod Chandran¹, Richard J. Cook² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose Psoriatic arthritis could lead to severe damage and disability. However, cases of improvement in joint damage over time have been reported in the literature.…
Abstract Number: 1575 • 2014 ACR/ARHP Annual Meeting
The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis
Lihi Eder¹, Cheryl Rosen², Vinod Chandran³ and Dafna D. Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Obesity is associated with an increased risk of developing psoriatic arthritis (PsA) in patients with psoriasis. This study aimed to assess whether obesity is…
Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting
Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients
Brigitte Michelsen¹, Andreas P. Diamantopoulos², Arthur Kavanaugh³ and Glenn Haugeberg^1,4, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway
Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…
Abstract Number: 1572 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial
Christopher J. Edwards¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Alvin Wells⁷, ¹University Hospital Southampton, Southampton, United Kingdom, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷Rheumatology & Immunotherapy Center, Franklin, WI
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
Abstract Number: 1571 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients with Psoriasis
M.C. Karreman¹, A.E.a.M. Weel^1,2, M. van der Ven¹, M. Vis³, I. Tchetverikov⁴, T.E.C. Nijsten⁵, J.M.W. Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose Musculoskeletal complaints(MSC) account for about 10% of the General Practitioner (GP) consultations1, in a small percentage the underlying disease is psoriatic arthritis (PsA). Evidence…
Abstract Number: 1570 • 2014 ACR/ARHP Annual Meeting
Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities
Stacy Tanner¹, Molly McFadden², Daniel Clegg³ and Jessica Walsh⁴, ¹Internal Medicine, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah, SLC, UT, ³Division of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT, ⁴Rheumatology Room 4B200 School of Medicine, University of Utah, Salt Lake City, UT
Background/Purpose People with psoriatic arthritis (PsA) have an increased risk for several comorbidities that negatively impact quality of life and survival. Defining the relationships between…
Abstract Number: 1569 • 2014 ACR/ARHP Annual Meeting
Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry
Alan Menter¹, Kim Papp², Gerald G. Krueger³, Matthias Augustin⁴, Francisco Kerdel⁵, Melinda Gooderham⁶, Kavitha Goyal⁷, Steve Fakharzadeh⁸, Wayne Langholff⁹, Jan Sermon¹⁰, Steve Calabro⁷ and David Pariser¹¹, ¹Baylor Research Institute, Dallas, TX, ²Probity Medical Research, Waterloo, ON, Canada, ³Dermatology, University of Utah, Salt Lake City, UT, ⁴University Clinics of Hamburg, Hamburg, Germany, ⁵University of Miami, Miami, FL, ⁶SKiN Centre for Dermatology, Peterborough, ON, Canada, ⁷Janssen Services, LLC, Horsham, PA, ⁸Janssen Services, LLC, Spring House, PA, ⁹Janssen Research and Development, LLC, Spring House, PA, ¹⁰Janssen-Cilag, Beerse, Belgium, ¹¹Eastern Virginia Medical School and Virginia Clinical Research, Inc, Norfolk, VA
Background/Purpose We evaluated persistency (treatment longevity) of biologics in patients (pts) with psoriasis (PsO), as well as with psoriatic arthritis (PsA) in the context of…
Abstract Number: 1568 • 2014 ACR/ARHP Annual Meeting
Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis
Hernán Maldonado-Ficco¹, Arane Thavaneswaran², Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The association between smoking and radiographic progression has been established in axial spondyloarthritides and rheumatoid arthritis (RA) but this association has not been established…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].